| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_675375ae4f084b4875d36afff6059afd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-34 |
| filingDate |
2017-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cbab7606f3da63e50b236a9300ce413
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82b9d00400db04cf8292456f3ee96972
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b913b8bbf157e8b04ce145c518e1454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e838144e35253e1775862cbfe87de28a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c40e227b54d1255b95d3f07bc7a29f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_150105ee0adabf6977a70402991a950e |
| publicationDate |
2020-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3597636-A1 |
| titleOfInvention |
Crystal forms of 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone |
| abstract |
A plurality of free base crystal forms of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and preparation methods therefor; further provided are the pharmaceutical formulations containing the crystal forms and a use thereof in the treatment of diseases, in particular in the treatment of angiogenic eye diseases. |
| priorityDate |
2017-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |